全文获取类型
收费全文 | 244篇 |
免费 | 22篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 20篇 |
妇产科学 | 5篇 |
基础医学 | 35篇 |
口腔科学 | 17篇 |
临床医学 | 22篇 |
内科学 | 49篇 |
皮肤病学 | 19篇 |
神经病学 | 16篇 |
特种医学 | 4篇 |
外科学 | 29篇 |
综合类 | 2篇 |
预防医学 | 13篇 |
眼科学 | 2篇 |
药学 | 24篇 |
中国医学 | 2篇 |
肿瘤学 | 6篇 |
出版年
2024年 | 3篇 |
2023年 | 19篇 |
2022年 | 19篇 |
2021年 | 38篇 |
2020年 | 27篇 |
2019年 | 22篇 |
2018年 | 16篇 |
2017年 | 16篇 |
2016年 | 18篇 |
2015年 | 15篇 |
2014年 | 7篇 |
2013年 | 7篇 |
2012年 | 17篇 |
2011年 | 12篇 |
2010年 | 7篇 |
2009年 | 1篇 |
2008年 | 3篇 |
2007年 | 3篇 |
2006年 | 4篇 |
2005年 | 2篇 |
2004年 | 4篇 |
2003年 | 6篇 |
2002年 | 2篇 |
排序方式: 共有268条查询结果,搜索用时 0 毫秒
1.
Yıldız Gizem Torun Bayram Meral Soylu Alper Kavukçu Salih 《International urology and nephrology》2021,53(2):391-392
International Urology and Nephrology - 相似文献
2.
3.
Gizem Tezel Selin Seda Timur Filiz Kuralay R. Neslihan Gürsoy Kezban Ulubayram Levent Öner 《Journal of drug targeting》2021,29(1):29-45
Abstract Synthetic micro/nanomotors (MNMs) are novel, self-propelled nano or microscale devices that are widely used in drug transport, cell stimulation and isolation, bio-imaging, diagnostic and monitoring, sensing, photocatalysis and environmental remediation. Various preparation methods and propulsion mechanisms make MNMs “tailormade” nanosystems for the intended purpose or use. As the one of the newest members of nano carriers, MNMs open a new perspective especially for rapid drug transport and gene delivery. Although there exists limited number of in-vivo studies for drug delivery purposes, existence of in-vitro supportive data strongly encourages researchers to move on in this field and benefit from the manoeuvre capability of these novel systems. In this article, we reviewed the preparation and propulsion mechanisms of nanomotors in various fields with special attention to drug delivery systems. 相似文献
4.
Mehmet Rasih Sonsoz Aytac Oncul Erdem Cevik Huseyin Orta Mustafa Yilmaz Elif Ayduk Govdeli Asli Nalbant Zeynep Gizem Demirtakan Mirac Tonyali Damla Durmus Ilkay Anakli Ozlem Polat Yunus Catma Naci Senkal Alpay Medetalibeyoglu Murat Kose Samim Emet Tufan Tukek 《The American journal of the medical sciences》2021,361(5):591-597
BackgroundThe information on electrocardiographic features of patients with coronavirus disease 2019 (COVID-19) is limited. Our aim was to determine if baseline electrocardiographic features of hospitalized COVID-19 patients are associated with markers of myocardial injury and clinical outcomes.MethodsIn this retrospective, single center cohort study, we included 223 hospitalized patients with laboratory-confirmed COVID-19. Clinical, electrocardiographic and laboratory data were collected and analyzed. Primary composite endpoint of mortality, need for invasive mechanical ventilation, or admission to the intensive care unit was assessed.ResultsForty patients (17.9%) reached the primary composite endpoint. Patients with the primary composite endpoint were more likely to have wide QRS complex (>120 ms) and lateral ST-T segment abnormality. The multivariable Cox regression showed increasing odds of the primary composite endpoint associated with acute respiratory distress syndrome (odds ratio 7.76, 95% CI 2.67–22.59; p < 0.001), acute cardiac injury (odds ratio 3.14, 95% CI 1.26–7.99; p = 0.016), high flow oxygen therapy (odds ratio 2.43, 95% CI 1.05–5.62; p = 0.037) and QRS duration longer than >120 ms (odds ratio 3.62, 95% CI 1.39–9.380; p = 0.008) Patients with a wide QRS complex (>120 ms) had significantly higher median level of troponin T and pro-BNP than those without it. Patients with abnormality of lateral ST-T segment had significantly higher median level of troponin T and pro-BNP than patients without.ConclusionsThe presence of QRS duration longer than 120 ms and lateral ST-T segment abnormality were associated with worse clinical outcomes and higher levels of myocardial injury biomarkers. 相似文献
5.
Alibaz-Oner Fatma Ergelen Rabia Ergenc Ilkay Seven Gizem Yazıcı Ayten Cefle Ayse Bes Cemal Atug Ozlen Direskeneli Haner 《Digestive diseases and sciences》2021,66(8):2750-2755
Digestive Diseases and Sciences - Behçet’s disease (BD) and Crohn’s disease (CD) cannot be easily differentiated in young adults presenting with nonspecific gastrointestinal (GI)... 相似文献
6.
Uzuner Selcuk Durcan Gizem Sahin Sezgin Bahali Kayhan Barut Kenan Kilicoglu Ali Guven Adrovic Amra Bilgic Ayhan Kasapcopur Ozgur 《Clinical rheumatology》2021,40(12):5025-5032
Clinical Rheumatology - Having a child with a chronic illness is a source of stress for the whole family, especially the primary caregiver. The aim of this study was to evaluate the associations... 相似文献
7.
Zehra Narli Ozdemir Guldane Cengiz Seval Ugur Sahin Atilla Uslu Mehmet Gunduz Sinem Civriz Bozdag Selami Kocak Toprak Meltem Kurt Yuksel Pervin Topcuoglu Isinsu Kuzu Muhit Ozcan Gunhan Gurman Osman Ilhan 《Indian journal of hematology & blood transfusion》2021,37(1):67
PurposeBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and poor prognostic hematological malignancy. There is still no standard treatment established for BPDCN patients. We aim to summarize the main clinical, biological features and treatment of 9 BPDCN patients.MethodsNine patients with BPDCN who had been diagnosed between July 2008 and December 2018 in Ankara University School of Medicine, were retrospectively evaluated.ResultsAll patients (n = 9) were male, median age was 64 (21–80). Five patients (55.6%) had bone marrow infiltration, 5 patients (55.6%) cutaneous lesions, 6 patients (66.7%) lymph node involvement, 2 patients (22.2%) central nervous system involvement and 2 patients (22.2%) spleen involvement at time of diagnosis. Complex karyotype was observed in 2 patients. CHOP was given to 5 patients (55.6%), hyper-CVAD to 2 patients (22.2%), fludarabine, cyclophosphamide and mitoxantrone to 1 patient (11.1%) and cyclophosphamide, etoposide, methylprednisolone to 1 patient (11.1%) as first line chemotherapy. Four patients (44.4%) underwent allogeneic hematopoietic stem cell transplantation (AHSCT) in complete remission (CR) 1. Venetoclax was given to a transplant ineligible patient who had skin and lymph node involvement, with the off-label use. The median follow-up time was 15.9 months (3–48.6 months). Estimated median overall survival was 15.9 + 1.6 (95% CI 12.7–19.1) months.ConclusionIntensive induction therapies followed by AHSCT in CR seems to be best approaches for patients with BPDCN. Thus, more effective treatment strategies particularly targeted therapies should be warranted to improve the survival of patients with this rare disease. 相似文献
8.
9.
10.
Mujgan Gungor Hatipoglu Sermet Inal Sahin Kabay Muhammet Kasim Cayci Ay?enur Deger Halil Isa Kuru Sayit Altikat Gizem Akkas 《Acta stomatologica Croatica》2015,49(4):325-330